Expression of neurotrophin receptors of the tyrosine kinase receptor (Trk) family is an important prognostic factor in solid tumors including neuroblastoma. High expression of TrkA (NTRK1) is associated with a favorable biology and outcome of neuroblastoma, whereas TrkB (NTRK2) is expressed on aggressive neuroblastomas with unfavorable outcome. To gain new insights into the global gene expression program resulting in these divergent biological phenotypes, we stably expressed either TrkA or TrkB in the human SH-SY5Y neuroblastoma cell line. Gene expression profiles were obtained from parental cells and transfectants activated by their ligands in a time course over 24 h using oligonucleotide microarrays. Basal activation of Trk receptors in the absence of exogenous ligand was sufficient to induce broad and divergent genetic changes. Global gene regulation following external ligand stimulation was surprisingly similar in SY5Y-TrkA and SY5Y-TrkB cells except for the differential expression of distinct novel target genes. Consistent with their divergent biological phenotype, SY5Y-TrkA cells were characterized by upregulation of proapoptotic genes and angiogenesis inhibitors, whereas SY5Y-TrkB cells demonstrated upregulation of genes involved in invasion or therapy resistance. We suggest that the transcriptional program of neuroblastoma cells is modulated by Trk-receptor expression and basal activation rather than by ligand-induced activation. Fine-tuning of the malignant phenotype may be achieved by additional ligand stimulation with subsequent activation of a few specific genes.
Expression of neurotrophin receptors of the tyrosine kinase receptor (Trk) family is an important prognostic factor in solid tumors including neuroblastoma. High expression of TrkA (NTRK1) is associated with a favorable biology and outcome of neuroblastoma, whereas TrkB (NTRK2) is expressed on aggressive neuroblastomas with unfavorable outcome. To gain new insights into the global gene expression program resulting in these divergent biological phenotypes, we stably expressed either TrkA or TrkB in the human SH-SY5Y neuroblastoma cell line. Gene expression profiles were obtained from parental cells and transfectants activated by their ligands in a time course over 24 h using oligonucleotide microarrays. Basal activation of Trk receptors in the absence of exogenous ligand was sufficient to induce broad and divergent genetic changes. Global gene regulation following external ligand stimulation was surprisingly similar in SY5Y-TrkA and SY5Y-TrkB cells except for the differential expression of distinct novel target genes. Consistent with their divergent biological phenotype, SY5Y-TrkA cells were characterized by upregulation of proapoptotic genes and angiogenesis inhibitors, whereas SY5Y-TrkB cells demonstrated upregulation of genes involved in invasion or therapy resistance. We suggest that the transcriptional program of neuroblastoma cells is modulated by Trk-receptor expression and basal activation rather than by ligand-induced activation. Fine-tuning of the malignant phenotype may be achieved by additional ligand stimulation with subsequent activation of a few specific genes.
Introduction
Neurotrophins mediate survival, differentiation, growth and apoptosis of neurons by binding to the tyrosine kinases TrkA, TrkB and TrkC or the p75 low-affinity neurotrophin receptor (Kaplan and Miller, 2000) . Upon binding of their specific ligands, Trk receptors dimerize and autophosphorylate cytoplasmic tyrosines. Signal transduction is processed through a diverse array of signaling pathways, including the Ras/MAPK-, the PLCg-and the PI3K-pathway (Patapoutian and Reichardt, 2001 ). The physiological functions of the neurotrophin receptors vary markedly, from the sculpting of the developing nervous system to the regulation of survival and regeneration of injured neurons (Conover and Yancopoulos, 1997) .
In the past years, Trk receptors have been identified as important prognostic factors in human malignancies of diverse origin, including neuroblastoma (Nakagawara et al., 1993 (Nakagawara et al., , 1994 . Recent experimental models elucidated the role of neurotrophin receptors in tumor biology. These studies revealed two interesting observations: (1) Despite of the high degree of sequence similarity and broadly overlapping signaling pathways, activation of the different Trk receptors leads to divergent biological responses and phenotypes when expressed in the same cell type. For example, high expression of TrkA in neuroblastomas is associated with a favorable biology and a good patient outcome, whereas TrkB is mainly expressed on aggressive neuroblastomas with a poor patient outcome (Nakagawara et al., 1993 (Nakagawara et al., , 1994 . (2) Critical elements of the Trk signaling pathway may vary between different tissues leading to a cell-type-specific response. For example, stimulation of TrkA by its specific ligand, nerve growth factor (NGF), leads to differentiation of neurons and neuroblastoma cells, whereas it induces proliferation of fibroblasts and apoptosis of medulloblastoma cells (Muragaki et al., 1997; Micera et al., 2001) . In contrast to its role in neuroblastoma, TrkB is associated with a favorable biology and good prognosis in medullary thyroid carcinoma (McGregor et al., 1999) , suggesting the response to Trk activation in tumor cells to be cell type specific.
The different Trk receptors might induce patterns of differential gene expression leading to favorable or unfavorable tumor cell phenotypes. In order to understand complex regulation patterns such as regulation via tyrosine receptor signaling, it is desirable to examine gene expression changes at different time points after receptor activation. We here describe an approach exploiting the power of transcriptional profiling to analyse the kinetics of gene expression changes over time in a defined in vitro model. The human SH-SY5Y neuroblastoma cell line, lacking endogenous expression of Trk receptors, served as a model system. Activation of TrkA or TrkB signaling pathways and the resulting phenotypes have been well studied in stable Trkexpressing SY5Y cells (Eggert et al., 2000b . Briefly described, activation of TrkA by NGF resulted in neuronal differentiation, growth inhibition, inhibition of angiogenesis and sensitization to drug-induced apoptosis (Eggert et al., 2000b . Whereas, activation of TrkB by its ligand brain-derived neurotrophic factor (BDNF) mainly resulted in enhanced proliferation and chemotherapy resistance of the cells (Ho et al., 2002) . Thus, the biological phenotype of the transfectants corresponds well with the excellent prognosis of primary neuroblastomas expressing high levels of TrkA, and the poor prognosis of neuroblastomas expressing TrkB. This study aims to gain deeper insights into how TrkA or TrkB expression alters the tumor cell phenotype. To this end, we analysed transcriptional profiles of the ligand-stimulated as well as unstimulated TrkA and TrkB receptors stably expressed in SH-SY5Y cells in a time course over 24 h, thereby monitoring early regulation events such as induction of 'immediate early genes' as well as downstream molecular targets.
Results
We stably expressed full-length constructs of TrkA, TrkB or the empty vector control (Vec) in the human neuroblastoma cell line SH-SY5Y as described in Materials and methods. All transfected single-cell clones used for this analysis demonstrated comparable expression levels of TrkA or TrkB protein and a low basal receptor activation indicated by tyrosine phosphorylation even in the absence of exogenous ligand (Figure 1 ). The biological phenotype of SY5Y-TrkA and SY5Y-TrkB cells correlated well with the prognostic role of Trk receptors in primary neuroblastomas Ho et al., 2002) .
Transfection of Trk receptors induces a set of differentially expressed genes even in the absence of exogenous ligand
We first analysed expression profiles of stable TrkA and TrkB transfectants in comparison to the parental SY5Y cell line and SY5Yvec in the absence of exogenous ligand. Genes differentially expressed in SY5Y and SY5Yvec cells (94 genes ¼ 0.75%) were excluded from further analysis. Interestingly, 727 genes were differentially expressed between either SY5Y-TrkA or SY5Y-TrkB and SY5Yvec according to our filter criteria (ANOVA, Po0.01, online supplement 1 and 2). Tukey post hoc testing (Table 1 ) identified 627 genes with significantly different expression levels between SY5Y-TrkA and SY5Y-TrkB cells, 228 of them with a mean fold change >2.8. Multidimensional scaling analysis revealed a larger Euclidian distance indicating a surprisingly low relatedness between expression profiles of SY5Y-TrkA in comparison to SY5Y-TrkB cells than between SY5Y-TrkA and SY5Yvec or SY5Y-TrkB and SY5Yvec cells (Figure 2a and supplement 3) . A heatmap further demonstrating the differences in the transcriptomes of SY5Y-TrkA and SY5Y-TrkB is shown in Figure 2b and more detailed in supplement 2. Correlation analysis of independent single-cell clones (Figure 2c ). Only 14 of all 299 regulated genes were differentially regulated (defined by a Pcc of oÀ0.4) between SY5Y-TrkA and SY5Y-TrkB cells. The genes with a Pcc oÀ0.4 are shown in Figure 2d . Upon ligand activation of SY5Y-TrkB or SY5Y-TrkA cells, a total of 299 genes were dynamically regulated in at least one time point according to our filtering criteria. Using a self-organizing map (SOM) algorithm (Tamayo et al., 1999) , these differentially regulated genes were grouped into 12 clusters. Cluster 1 contained genes that have previously been identified as immediate early genes, and a subset of these were induced within 30 min ( Figure 2e , cluster 1A). Among these, transcription factors previously known to be induced by growth factors (Fambrough et al., 1999) were observed (e.g. junB, fos and ETR101). A second, but distinct group of immediate early genes was highly induced 1 h after ligand addition, and was consequently grouped into a 'delayed' cluster ( Figure Invasiveness/tumor matrix interaction MCSP (membrane chondroitin sulfate proteoglycan) was previously shown to be involved in the invasive behavior of melanoma cells (Iida et al., 2001) . MCSP belonged to the most diversely regulated genes in this study (Pearson correlation coefficient oÀ0.4, Figure 2d ), and was markedly upregulated after TrkB activation by BDNF on both mRNA and protein levels ( 
Discussion
The use of microarray technology to obtain timedependent expression profiles is a fascinating tool for monitoring global changes in gene expression on a cellular level. Up until now, this has been widely applied for pharmacogenomics, while reports on transcriptional changes induced by ligand-receptor interactions remain limited (Fambrough et al., 1999; Iyer et al., 1999) . In this study, we applied genome-scale gene expression analysis to a well-defined neuroblastoma model in order to gain insight into the dynamics of neurotrophin receptorrelated effects on tumor cell phenotypes. The TrkA and TrkB receptors send divergent biological signals, making this system a useful model case to study. The results of our study demonstrate that (1) basal activation of the different Trk receptors results in patterns of differentially expressed genes and (2) very few genes are differentially regulated in response to ligand stimulation. Additionally, this study has identified new Trk receptor target genes having potential biological significance for the neuroblastoma cell phenotype. The most surprising observation from this study was the remarkable difference in the basal expression profiles of TrkA-and TrkB-expressing SY5Y cells, which could not be explained by clonal variation (Figure 2a, b) . There are two possible explanations for the basal receptor activation indicated by low autophosphorylation ( Figure 1 ): (1) Overexpression of target genes due to very efficient transfection, in particular when retroviral vectors are used, has often been observed. It has also been previously suggested that physiological overexpression of certain receptor types may lead to dimerization of receptor monomers resulting in phosphorylation and basal activation (Penuel et al., 2002) . This type of crosstalk has been suggested to contribute to the ability of mature neurons to survive in the absence of neurotrophin (Orike et al., 2001) . (2) Low levels of autophosphorylation may also be caused by a physiological level of basal activation, as it has been shown for G protein-coupled receptors (Teitler et al., 2002) . A scaffolding protein binding to G protein-coupled receptors, GIPC, also interacts with Trks (Lou et al., 2001) . It has been suggested that adenosine might use such scaffolds to recruit and cluster Trk receptors at the plasma membrane Lou et al., 2001) . In agreement with the hypothesis of a constitutive basal Trk receptor activation, several biological responses of Trk-expressing neuroblastoma cells, including growth inhibition or inhibition of angiogenesis, have previously been shown to be independent of exogenous ligand activation (Haapasalo et al., 1999; Eggert et al., 2002) . The physiological relevance of these findings remains to be elucidated, as data on distribution or normal concentrations of neurotrophins in human normal or neoplastic sympathetic nervous tissue are not yet available. Thus, constitutive basal activation of Trk receptors in primary neuroblastomas might lead to biological effects itsself, independently of neurotrophin concentrations in the surrounding tissue. Additional (Figure 2c) , and subsequently similar regulation of effector genes (Figure 2d, e) . However, it remains unclear, how this similar gene regulation gives rise to the divergent phenotypes of TrkA-and TrkB-expressing neuroblastoma cells.
We discuss three possible models for the development of phenotypical differences. (1) The observed phenotypes may be due to additive effects from minor differences between the amplitude and time course of expression changes. A similar idea emerged in previous studies addressing phosphorylation of proteins involved in signal transduction (Iyer et al., 1999) . Changes in phosphorylation kinetics (level as well as time course) of signaling proteins including the Raf-Mek-Erk cascade have been linked to divergent effects (Vaudry et al., 2002) . Equivalent mechanisms may also function in gene regulation. (2) The divergent phenotype induced by similar gene regulation may be due to the different transcriptional backgrounds. We have shown here that large differences in the transcriptome of SY5Y-TrkA and SY5Y-TrkB occured due to basal receptor activation. The contribution of this background to the phenotypic effects of additional changes in gene expression should not be underestimated. (3) The opposing phenotypes may be due to expression changes of a few genes, shown to be differentially regulated in our model. Taken in this light, these single genes become more interesting, since they may play important biological roles. Aside from our attempts to view Trk receptor signaling effects on the transcriptome level, we also focused on the most interesting target genes that may underlie the biological difference between TrkA-and TrkB-positive tumors. It is beyond the scope of this paper to provide a discussion of all observed changes and their biological implications. However, several interesting features deserve mention.
Therapy resistance
Expression of TrkB and BDNF has been suggested to protect neuroblastoma cells from chemotherapyinduced toxicity in previous studies (Scala et al., 1996; Middlemas et al., 1999a, b; Ho et al., 2002; Jaboin et al., 2002) . Enhanced resistance to chemotherapy was also observed in SY5Y-TrkB cells in comparison to SY5Y cells in our study (Figure 3d ). Our microarray-derived results offer a possible explanation for this biological effect: the multidrug resistance (MDR) gene mdr1 and its corresponding protein, P-glycoprotein (P-gp), were upregulated in BDNF-activated SY5Y-TrkB cells (Figure 3a-c) . In contrast to our data, a previous study by Scala et al. (1996) reported no differences in mdr1 expression after BDNF-treatment of SY5Y cells, induced to express TrkB by treatment with retinoic acid. There are two possible explanations for this discrepancy:
(1) Since we observed a dose-dependent effect of TrkB expression on chemotherapy resistance of SY5Y cells in a previous study (Ho et al., 2002) , high expression of TrkB might also be needed for the full effect of BDNF activation on mdr1 expression. It is likely that TrkB expression levels in SY5Y cells after treatment with retinoic acid are lower than expression levels reached in the stably expressing cell lines produced by retroviral infection used in our study. Lower TrkB expression might then not be sufficient to detect effects of BDNF on mdr1 expression. (2) The amount of BDNF used for SY5Y activation by Scala et al. was only 30 ng/ml for a maximum time of 6 h, whereas we observed a maximum effect on mdr1 expression after 24 h activation with 50 ng/ml BDNF. We cannot exclude, however, that the high levels of TrkB and BDNF used in our cell culture (Scala et al., 1996) . MDR-3 protein expression, previously unlinked to human neuroblastoma, is reported to act in vitro on drug targets similar to those of P-gp (Smith et al., 2000) . The significant downregulation of mdr3 in SY5Y-TrkA cells might contribute to the enhanced drug sensitivity of these cells. The clinical impact of these findings remains to be determined, since the prognostic value of P-gp expression in neuroblastoma is still a matter of debate. However, a close correlation between expression of the multidrug resistance-associated protein (MRP) gene and the MYCN oncogene as well as evidence for MRP expression as a powerful independent predictor of poor outcome in neuroblastoma has been shown before (Norris et al., 1996; Haber et al., 1999) . The fact that resistance of SY5Y-TrkB cells to treatment with cisplatin, previously reported to be mdr1 independent (Fujiwara et al., 1990) , was also enhanced, suggests that additional genes might be involved in mediating therapy resistance of TrkBexpressing neuroblastoma cells. Similar results were obtained by triplicate analysis of all three drugs in a time course from 24 to 96 h using clinically achievable dose ranges molecular-weight melanoma-associated antigen (HMW-MAA)) as immunogens to implement active specific immunotherapy is a novel experimental strategy in patients with malignant melanoma (Ferrone and Wang, 2001 ). In light of our results, MCSP might also be an interesting molecular target for immunotherapy of neuroblastoma patients. An effect of TrkB signaling on the invasive activity of neuroblastoma cells has been described previously (Matsumoto et al., 1995) . However, up until now no potential target genes responsible for the observed invasive effect have been identified.
Invasiveness

Angiogenesis
We previously reported the downregulation of angiogenic stimulators such as VEGF in SY5Y-TrkA cells and their corresponding xenografts in nude mice . We now demonstrate that, in addition, inhibitors of angiogenesis (i.e. s-flt1) are upregulated in SY5Y-TrkA cells at both the mRNA and protein levels (Figure 5a-c) . Functional analysis using the endothelial cell proliferation assay in the presence of either recombinant VEGF or bFGF further indicates the presence of angiogenic inhibitors in CM from SY5Y-TrkA cells (Figure 5d ). Basic FGF is a strong stimulator of BBCE proliferation. Our results demonstrate that this effect is only partly inhibited by the presence of angiogenesis inhibitors in CM from SY5Y-TrkA cells. This supports the hypothesis that the VEGF antagonist, s-flt1, may be a major angiogenesis inhibitor in SY5Y-TrkA CM, as in contrast to bFGF-mediated BBCE proliferation, VEGF-induced BBCE proliferation is almost completely inhibited (Figure 5d ). Whether additional factors in SY5Y-TrkA CM contribute to bFGF inhibition or whether these effects are mediated in part via VEGF signaling remains to be elucidated. However, the upregulation of angiogenic inhibitors is likely to be an important feature contributing to the reduced tumorigenicity of TrkA-expressing neuroblastoma cells. Transfected SY5Y cells were cultured in RPMI þ 10% FCS7recombinant IGFBP-3 (100 ng/ml) and/or IGF-1 (10 ng/ml) as indicated, and cells were counted after 72 h. Similar results were obtained for higher concentrations of IGF-1 (50 and 100 ng/ml). Data points are the mean of three independent experiments (error bars, 7s.d.). Representative results of experiments with two different cell clones are shown modulator of IGF bioactivity and as a direct growth inhibitor in the extravascular tissue compartment, where it is expressed in a highly regulated manner (Ferry et al., 1999a, b) . IGFBP-3 was identified as the gene with the most divergent regulation pattern upon ligand application (Figure 2d ). Its role in cancer biology remains controversial, since increased IGFBP-3 expression levels were associated with progressive disease in recent studies of colorectal cancer (Ma et al., 1999) , whereas high IGFBP-3 expression was correlated with favorable outcome in breast cancer patients (Descamps et al., 2001) . Activation of the IGF-I receptor by IGF-I or IGF-II has been reported to induce proliferation, prevent apoptosis and enhance tumorigenesis of SY5Y cells (Leventhal et al., 1995; Singleton et al., 1996; Meyer et al., 2001) . Interestingly, upregulation of IGF-II expression has previously been reported as a feature of TrkA, but not TrkB, activation in SY5Y cells (Kim et al., 1999) . Despite this finding, high TrkA expression results in growth inhibition and decreased tumorigenesis of SY5Y cells (Eggert et al., 2000b . Here, recombinant IGFBP-3 inhibited proliferation of neuroblastoma cells in the absence and presence of IGF. Thus, the significant upregulation of IGFBP3 in SY5Y-TrkA cells as well as its downregulation in SY5Y-TrkB cells provides a possible explanation for the characteristic growth behavior of the respective cells. IGFBP-3 may contribute to growth inhibition by inhibiting the IGF-I and IGF-II-mediated effects predominantly in SY5Y-TrkA cells. However, the IGF network is very complex and not only controlled on transcript but also on translational level (i.e. by proteolytic cleavage of IGFBP binding proteins). Therefore, assessment of the contribution of the IGF family to neuroblastoma biology has to be answered on proteome rather than transcriptome level.
Conclusions
The results presented here provide a picture of the molecular program of Trk receptor signaling leading to effects on the tumor cell phenotype. Trk receptor activation obviously elicits a complex gene expression program that appears to be initiated at two different levels: (1) A basal level of receptor activation leads to a broadly different background of gene expression between TrkA-and TrkB-expressing neuroblastoma cells. 
Materials and methods
Cell culture, transfection and characterization of transfected cell lines
Cells were grown in RPMI medium supplemented with 10% FCS, L-glutamine and gentamicin. In the FCS used, neither BDNF nor NGF was detectable by ELISA. SH-SY5Y is a subclone of the human SK-N-SH neuroblastoma cell line described previously (Biedler et al., 1973) . Full-length TrkA or TrkB cDNA were cloned into the retroviral expression vector pLNCX or pLNCX2 (Clontech, Palo Alto, CA, USA), respectively, as described (Eggert et al., 2000b) . For confirmation of target gene expression in a second cell line, TrkA was also stably expressed in IMR5 human neuroblastoma cells. Transfected cells were selected with 500 mg/ml G418 (Sigma, Munich, Germany) and subcloned by limiting dilution to obtain single-cell clonal lines. As negative controls, SY5Y cells were infected with a retrovirus bearing the empty pLNCX retroviral vector (SY5Yvec). Sequencing confirmed the identity of all transfectants. In contrast to SY5Yvec cells, the SY5Y-TrkA and SY5Y-TrkB cell lines demonstrated high and comparable expression of the inserted receptor on both the mRNA and protein levels (Figure 1) (Eggert et al., 2000b) . These expression levels are several fold higher than endogenous levels in neuroblastoma cell lines, but comparable to mRNA levels measured by RT-PCR in tumor samples with high Trk-receptor expression. Transfected cells expressed low amounts of the endogenous ligands NGF and BDNF, as analysed by ELISA of the CM (data not shown). Both receptors were autophosphorylated at low levels prior to ligand stimulation. A strong increase in receptor autophosphorylation was seen after addition of NGF or BDNF to SY5Y-TrkA and SY5Y-TrkB cells, respectively (Figure 1 ) (Eggert et al., 2000b) .
Oligonucleotide microarray analysis
Cells were lysed in Trizol (Gibco) in the absence of neurotrophins or at the time points after NGF (100 ng/ml) or BDNF (50 ng/ml) addition. Total mRNA was prepared using the Qiagen RNeasy Mini Kit (Qiagen, Hilden, Germany). Fragmentation of cRNA, hybridization to U95Av2 microarrays (Affymetrix Inc., Santa Barbara, CA, USA), washing, staining and scanning in a GeneArray scanner (Agilent, Palo Alto, CA, USA) were performed according to the manufacturer´s recommendations. Signal intensities and decision calls for further analysis were determined using GeneChip Microarray Suite (MAS) 5.0 software (Affymetrix). Scaling across all probe sets of a given array to an average intensity of 1000 units compensated for variations in the amount and quality of cRNA samples as well as other experimental variables.
Data processing and analysis
Data storage Expression data and gene annotations were stored in a relational database (Oracle9i). Annotation was obtained from public databases (e.g. Unigene, http:// www.ncbi.nlm.nih.gov/entrez/query.fcgi?db ¼ unigene and Netaffx from Affymetrix, http://www.affymetrix.com/analysis/index.affx) or from the output of several prediction tools (e.g. TargetP (Emanuelsson et al., 2000) ).
Data processing Low level analysis (image to raw expression value) was performed with Affymetrix MAS5.0. Absolute expression signals as well as the mean probe level fold changes (expressed as SigLogRatio, i.e. log-transformation of fold change using base 2), presence/absence calls and change calls were calculated. All chips were scaled to a target intensity of 1000.
Gene filtering Data Mining Tool (DMT) 3.0 (Affymetrix) and scripts called within R environment (http://www.rproject.org/) were used for gene filtering. (A) The criteria for a transcript to be called differentially expressed between samples in the kinetic analysis stimulation were: a. signal X400 and call ¼ 'P' ('Present') in at least one sample and b. DiffCall ! ¼ 'NC' (no 'no change') and SigLogRatio X1.3 (i.e. fold change X2.5) in comparison of any time points within either SY5Y-TrkA or SY5Y-TrkB. (B) The criteria of a transcript to be included into the overall similarity analysis of unstimulated clones (i.e. calculation of Euclidian distance, correlation coefficient and multidimensional scaling (MDS) based on Euclidian distance) were: a. signal X400 and call ¼ 'P' ('Present') in at least one sample and b. DiffCall ! ¼ 'NC' (no 'no change') and SigLogRatio X1.5 (i.e. fold change X2.8) in comparison of any two samples (2132 genes passed this filter). (C) The criteria of a transcript to be included in the statistical analysis of the set of unstimulated clones were: signal X400 and call ¼ 'P' ('Present') in at least four of 15 (3 Â 5) samples (5688 genes passed this filter).
MDS Similarity calculation, MDS and statistical analysis of the distance matrices (supplement 3) were performed within the R 1.9.0. environment (stats package). For MDS, Spotfire Decision Site 7.0 (Spotfire Inc., Somerville, MA, USA) was used as a graphical front-end.
Statistical analysis of unstimulated clones A one-way analysis of variance (ANOVA) was calculated using R 1.9.0. (stats package) to assess differential gene regulation between SY5Y-TrkA, SY5Y-TrkB and control. P-values were corrected for multiple testing using the Benjamini&Hochberg-Algorithm (R 1.9.0, multtest package), genes with Po0.01 were considered to be differentially expressed. Tukey post hoc testing (R 1.9.0, stat package) was used to analyse individual differences between subgroups (SY5Y-TrkA, SY5Y-TrkB, SY5Yvec), the significance level was set to Po0.01.
Cluster analysis For hierarchical cluster analysis, expression levels below 400 were set to 400 and transcripts with a FC below 2.5 were omitted. One probe was displayed for genes represented by more than one probe (n ¼ 40). Genesis (Sturn et al., 2002) was used for hierarchical and SOM clustering as well as to generate heat maps. The criteria used for optimization of SOM clusters were: (1) no empty cluster, (2) no similar kinetics in two different clusters, (3) no different kinetics in one cluster.
Online supplement Additional data are available as online supplement at (http://www.uni-essen.de/kinderklinik/onkolab/ oncogene_04/.
Semiquantitative RT-PCR
Semiquantitative RT-PCR was performed by standard techniques using 1 mg of total RNA. Primer sequences specific for human MCSP, MDR1, MDR3, TSP2, sFlt1, IGFBP3 and GAPD are available upon request. The housekeeping gene, GAPDH, was coamplified as an internal standard control as previously described (Eggert et al., 2000a) .
Protein studies
Expression of MCSP and the MDR-1 protein (P-gp) were monitored by FACS analysis after neurotrophin treatment for 24 h. Cells were trypsinized, washed with PBS and incubated with the murine MCSP-NG2 monoclonal antibody (Becton Dickinson), P-gp antibody MRK-16 (Kamiya Biomedical, Seattle, WA, USA) or isotype control. After incubation at 41C for 20 min, cells were washed with PBS, incubated with the FITC-conjugated secondary antibody for 15 min at 41C and analysed in a Beckman Coulter EpicsXL4 using EXPO32 software (Beckman Coulter, Krefeld, Germany).
SY5Yvec, SY5Y-TrkA and SY5Y-TrkB cells were grown on slides and analysed using immunohistochemistry. The anti-MCSP monoclonal antibody, CGP76873 (a generous gift from S Ferrone and Novartis), was used at a dilution of 1 : 400. For negative controls, the primary antibody was omitted and substituted with normal mouse IgG (Vector Laboratories, Burlington, CA, USA). After incubation with an anti-mouse secondary antibody, the immune complex was visualized using the StrAviGen Super Sensitive kit (BioGenex Laboratories, San Ramon, CA, USA) with fast red as a chromogen. Sections were counterstained with hematoxylin.
S-flt protein levels were quantified in supernatants of cell cultures using a luminescence-based ELISA (Research Diagnostics, Flanders, NJ, USA). IGFBP-3 concentrations in serum-free CM from indicated cell lines were determined by a radioimmunoassay (RIA) (Mediagnost, Reutlingen, Germany).
Functional assays
Treatment with either a chemotherapeutic agent or IGF-I/ IGFBP-3 was applied as indicated in the results. A colorimetric MTT assay was performed as described (Mosmann, 1983) after either 2 days (chemotherapy) or 4 days (IGFBP-3), respectively.
A matrigel cell invasion assay was performed as described previously (Neaud et al., 2000) . Briefly, 8 mm polycarbonate pore size filters were coated with Matrigel (15 mg) and inserted into 12-well plates (Gibco). RPMI with 2% FCS was added to the upper compartment, RPMI in the lower compartment contained 15% FCS, 1 mg/ml fibronectin1 (Gibco) and the respective neurotrophin. Isotype-control or 15 mg/ml anti-MCSP-mAb was added once at the beginning of the experiment (0 h) to both the upper compartment and the Matrigel layer. Cells (1 Â 10 6 ) were seeded into the upper well, and incubated for 72 h. Cells migrating through the filter were H þ E stained and visualized microscopically ( Â 400).
The endothelial proliferation assay used to evaluate the effects of 50-fold concentrated CM was performed using BBCE as previously described .
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